Nurix Therapeutics (NRIX) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 0.78.
- Nurix Therapeutics' Equity Ratio fell 56.14% to 0.78 in Q4 2025 from the same period last year, while for Nov 2025 it was 0.78, marking a year-over-year decrease of 56.14%. This contributed to the annual value of 0.78 for FY2025, which is 56.14% down from last year.
- As of Q4 2025, Nurix Therapeutics' Equity Ratio stood at 0.78, which was down 56.14% from 0.71 recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Equity Ratio ranged from a high of 0.79 in Q4 2024 and a low of 0.54 during Q1 2024
- In the last 5 years, Nurix Therapeutics' Equity Ratio had a median value of 0.74 in 2023 and averaged 0.72.
- Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 2710.52% in 2024, then soared by 4488.31% in 2025.
- Quarter analysis of 5 years shows Nurix Therapeutics' Equity Ratio stood at 0.72 in 2021, then rose by 1.5% to 0.73 in 2022, then fell by 22.63% to 0.56 in 2023, then surged by 39.64% to 0.79 in 2024, then dropped by 0.56% to 0.78 in 2025.
- Its last three reported values are 0.78 in Q4 2025, 0.71 for Q3 2025, and 0.76 during Q2 2025.